Clear Creek Financial Management LLC Has $1.62 Million Stock Position in Gilead Sciences, Inc. $GILD

Clear Creek Financial Management LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 14,623 shares of the biopharmaceutical company’s stock after buying an additional 1,422 shares during the quarter. Clear Creek Financial Management LLC’s holdings in Gilead Sciences were worth $1,621,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter worth about $25,000. Activest Wealth Management raised its holdings in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter worth about $29,000. Colonial Trust Advisors raised its holdings in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares during the last quarter. Finally, Core Alternative Capital raised its holdings in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 241 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.3%

NASDAQ:GILD opened at $116.74 on Friday. Gilead Sciences, Inc. has a one year low of $84.17 and a one year high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company’s 50-day simple moving average is $114.57 and its 200 day simple moving average is $110.19. The firm has a market capitalization of $144.85 billion, a P/E ratio of 23.26, a PEG ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences’s payout ratio is 62.95%.

Insider Activity at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company’s stock, valued at $978,880.80. The trade was a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $9,402,130 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on GILD shares. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the company from $108.00 to $127.00 in a research report on Friday, August 8th. UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Finally, Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $118.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.